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Summary We investigated hyaluronidase activity in gynaecological normal and malignant tissues. Hyaluronidase activity in culture medium
of tissue specimens was detected by hyaluronic acid zymography and quantified by densitometry. Hyaluronidase activity was shown as one
dominant band (molecular weight 65 kDa) at pH 3.5. Hyaluronidase activity was significantly higher in normal ovary (P < 0.05) and normal
endometrium (P < 0.05) than in normal cervix. One dominant 65-kDa hyaluronidase was expressed in 100% (14 out of 14) of ovarian cancer
tissues and in 91% (10 out of 11) of endometrial cancer tissues. However, hyaluronidase activity was not observed in cervical cancer tissues.
Hyaluronidase activity was significantly higher in ovarian (P< 0.001) and endometrial (P< 0.01) cancer tissues than in cervical cancer tissue
and was significantly higher in ovarian cancer tissue than in endometrial cancer tissue (P < 0.05). These facts suggest that the cancer cells
make use of the original characteristic of the organ to invade and metastasize. Moreover, these results reflect the difference in metastatic
forms and are suggestive of a strong relationship between hyaluronidase activity and invasion and metastasis of ovarian and endometrial
cancers compared with cervical cancer.
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One tumour cell property that is a prerequisite for metastasis is the
ability to degrade connective tissue extracellular matrix and base-
ment membrane components, which constitute barriers forinvading
tumour cells. Indeed, metastatic tumour cells have been shown to
produce enzymes, such as proteinases and glycosidases, that are
capable of degrading the various components of the extracellular
matrix (Nakajima et al, 1988; Duffy, 1992; Baker et al, 1994).
The prevalent mechanism for the spread in a number of human
neoplasms arising from abdominal organs, such as the stomach
(Baba et al, 1992), ovary (Rosman et al, 1994) and other sites, is
the extension of tumour cells from the primary tumour into the
peritoneum, although other mechanisms such as lymphatic and
haematogenous spread may also occur. Tumour cells present in the
peritoneum may be removed from the abdominal cavity via
lymphatics originating on the inferior surface of the diaphragm in
a manner similar to that observed for the removal of foreign
particles from the peritoneal cavity. Tumour cell obstruction of
peritoneal lymphatics may subsequently occur, resulting in the
development of carcinomatous ascites (Hirabayashi and Graham,
1970). The formation ofascites fluid can then further facilitate the
spread oftumour cells to other sites within the peritoneal cavity.
The peritoneum, omentum and bowel surfaces are the most
frequent sites for implantation of metastatic cancer cells, although
other organs are also at risk. The outer lining of these metastatic
sites comprises a single layer ofhighly flattened mesothelial cells
with underlying extracellular matrix. For cells to establish foci on
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these surfaces, the cells need to attach to the mesothelial cell
surface and penetrate the underlying stroma.
Human mesothelial cells produce large amounts of hyaluronic
acid (Asplund et al, 1993), a high molecular mass polysaccharide
found in the extracellular matrix and one of a group ofconnective
tissue polysaccharides containing hexosamine collectively known
as glycosaminoglycans. Therefore, it is necessary to degrade
hyaluronic acid for cancer cells to invade the peritoneum.
Hyaluronidase is considered to play a role here. However, studies
of glycosaminoglycan-degrading enzymes in cancer tissues are
still limited as currently available techniques do not have adequate
sensitivity for detecting small amounts ofthe enzymes.
In this study, hyaluronidase activity in clinically different
metastatic types ofovarian cancer, endometrial cancer and cervical
cancer tissues was evaluated by means of substrate gel electro-
phoresis as developed by Miura et al (1995), which is capable of
detecting minute amounts of hyaluronidase; activity in normal
ovarian, endometrial and cervical tissues was also evaluated.
MATERIALS AND METHODS
Tissue samples
We examined cancer tissues obtained from 14 patients with
ovarian cancer, 11 with endometrial cancer and six with cervical
cancer by surgical resection after written informed consent was
obtained from each patient. The sites from which the specimens
were removed were confirmed to be cancerous by histological
examination. Histological type and differentiation of the tumours
were determined by one pathologist. Tables 1, 2 and 3 summarize
the clinical data from patients. Among the patients with ovarian
cancer, seven had stage I, six had stage III and one had stage IV
disease. The ovarian cancer cases demonstrated different histolog-
ical types. The histological types were serous cystadenocarcinoma
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Table 1 Clinical data of patients with ovarian cancer
Patient no. Age (years) Stage Histological type Differentiation Medium-control
OV-1 54 Ic Endometrioid adenocarcinoma Gl 1.06
OV-2 48 IlIc Serous cystadenocarcinoma G3 1.17
OV-3 35 la Serous cystadenocarcinoma G2 1.06
OV-4 45 Illc Endometrioid adenocarcinoma Gl 0.687
OV-5 75 Illc Mucinous cystadenocarcinoma Gl 0.108
OV-6 39 Illc Clear cell adenocarcinoma Gl 0.596
OV-7 50 Ic Endometrioid adenocarcinoma Gl 0.434
OV-8 59 Ic Serous cystadenocarcinoma G3 0.542
OV-9 14 Ic Yolk sac tumour _a 2.00
OV-10 66 Illb Unclassified adenocarcinoma G3 0.170
OV-11 57 Illc Serous cystadenocarcinoma G3 0.170
OV-12 54 Ic Clear cell adenocarcinoma Gl 4.07
OV-13 52 Ic Clear cell adenocarcinoma G2 4.49
OV-14 36 IV Clear cell adenocarcinoma G3 0.972
aDifferentiation does not exist for yolk sac tumour.
Table 2 Clinical data of patients with endometrial cancer
Patient no. Age (years) Stage Histological type Differentiation Myometrial invasion (%) Medium-control
EN-1 57 IlIc Endometrial type G2 60 0.421
EN-2 60 Ila Endometrial type G3 70 0.295
EN-3 39 Ic Endometrial type Gi 60 0.482
EN-4 54 lb Endometrial type Gl 50 0.123
EN-5 57 Ic Endometrial type G3 80 0.332
EN-6 43 lb Endometrial type Gl 10 0
EN-7 53 lb Endometrial type Gl 20 0.152
EN-8 68 lb Endometrial type Gl 10 0.233
EN-9 72 lb Hepatoid tumour -a 10 2.80
EN-10 51 lb Endometrial type G3 10 0.715
EN-11 48 llb Endometrial type G2 80 0.129
aDifferentiation does not exist for hepatoid tumour.
Table 3 Clinical data of patients with cervical cancer
Patient no. Age (years) Stage Histological type Lymph node involvement
C-i 31 lb Squamous cell carcinoma +
C-2 61 lb Squamous cell carcinoma
C-3 51 Illa Squamous cell carcinoma a
C-4 43 lb Squamous cell carcinoma
C-5 72 Ilb Squamous cell carcinoma a
C-6 29 llb Squamous cell carcinoma +
aPatient did not undergo lymphadenectomy. -, Negative; +, positive.
in four patients, mucinous cystadenocarcinoma in one patient,
clear cell adenocarcinoma in five patients, endometrioid adenocar-
cinoma in two patients' unclassified adenocarcinoma in one
patient and yolk sac tumour in one patient. Among patients with
endometrial cancer, eight had stage I, two had stage II and one had
stage III disease. The histological types were endometrial type in
ten patients and hepatoid cell carcinoma in one patient. Among
patients with cervical cancer, three had stage I, two had stage II
and one had stage III disease. Histologically, all cases of cervical
cancer were of squamous cell type.
Normal ovarian, endometrial and cervical tissues were obtained
from patients with uterine myoma.
Detection of hyaluronidase activity
Sliced tissues were extensively washed in phosphate-buffered
saline to remove contaminating red blood cells and incubated in
RPMI 1640 medium at a concentration of 0.1 g ml-' for 4 h at
37°C. Aliquots of 0.5 ,l of culture medium were subjected to
SDS-polyacrylamide gel electrophoresis in Laemmli's system
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Figure 1 Zymographic profiles of hyaluronidase activities in culture supernatants of normal ovary (A), endometrium (B) and cervix (C)
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Figure 2 Relative activity ratio of culture medium hyaluronidase to the
control serum hyaluronidase. Activity ratio was calculated as ratio of peak
areas
(Laemmli, 1970) using 10% gels of 1 mm thick to which
170 ,ug ml-' ofhyaluronic acid had been added andcopolymerized.
After electrophoresis, the gels were washed with 2.5% Triton X-
100 and incubated for 20 h at 37°C in reaction buffer (100 mM
acetate buffer, pH 3.5 or pH 5.0, containing 150 mm sodium chlo-
ride). The gels were treated with 0.1 mg ml-l pronase solution
(100 mm Tris-HCl, pH 8.0, containing 20 mm sodium chloride)
for 2 h at 370C to prevent artifacts following incubation. The gels
were then washed in 25% ethanol-10% acetic acid, stained with
0.5% Alcian blue in 25% methanol-10% acetic acid for 1 h and
washed in 25% methanol-10% acetic acid. The gels were stained
with 0.2% Coomassie brilliant blue in 50% methanol and 10%
acetic acid for 1 h and washed in 20% methanol and 10% acetic
acid. Hyaluronidase activity was detected as unstained bands
corresponding to the positions ofthe migrated enzyme.
Aliquots of the same serum sample obtained from the patient
with endometrial cancer was electrophoresed on each gel as a
control.
Densitometric analysis of hyaluronidase activity
Photographs of the gels were scanned with a densitometer
(Shimazu CS-930, Shimazu, Kyoto, Japan) using the reflection
mode. Hyaluronidase activity was indicated as the negative peak
ofthe densitometric curve. The relative activity ratio ofthe culture
medium to the control serum hyaluronidase was calculated as the
ratio ofeach peak area.
Statistical comparisons between cancer tissues were performed
using the Mann-Whitney test, which is used to determine the
significance ofdifferences between each non-parametric factor.
RESULTS
Hyaluronidase activity was measured in tissue specimens using the
method described in the Materials and methods section using
hyaluronic acid zymography.
Figure 1 shows the results of zymography in normal ovarian,
endometrial and cervical tissues. Hyaluronidase activity was
shown as one dominant band (molecular weight 65 kDa) at
pH 3.5. This 65-kDa hyaluronidase was expressed brightly in all
cases of normal ovarian and endometrial tissues but was
expressed slightly in normal cervical tissues. In normal ovarian,
endometrial and cervical tissues, the mean medium-control
ratios were0.495 ± 0.118, 0.318 ± 0.186 and 0.000478 ± 0.000955
respectively. These results are plotted in Figure 2. The ratios
were significantly higher in normal ovarian tissue (P < 0.05) and
normal endometrium (P < 0.05) than in normal cervical tissue.
The results of zymography in ovarian cancer, endometrial
cancer and cervical cancer tissues are shown in Figures 3, 4 and 5
respectively. The 65-kDa hyaluronidase was expressed in 100%
(14 out of 14) ofovarian cancer tissues and in 91% (10 out of 11)
of endometrial cancer tissues. However, hyaluronidase activity
was not observed in cervical cancer tissues. High molecular
weight bands were detected in lane 13 ofovarian cancer tissue and
lane 5 of endometrial cancer tissue. These two hyaluronidases
are currently under investigation. In ovarian cancer, the
medium-control ratio ranged from 0.108 to 4.49, with a mean
value of 1.25 ± 1.38. In endometrial cancer, the ratio ranged from
0 to 0.715, with a mean value of0.517 ± 0.783. There was no band
in cervical cancer. These results were plotted in Figure 2 and
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Figure 3 Zymographic profiles of hyaluronidase activities in culture
supernatants of ovarian cancer tissues. Lane numbers correspond to patient
numbers in Table 2
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Figure 4 Zymographic profiles of hyaluronidase activities in culture
supernatants of endometrial cancer tissues. Lane numbers correspond to
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Figure 5 Zymographic profiles of hyaluronidase activities in culture
supernatants of cervical cancer tissues. Lane numbers correspond to patient
numbers in Table 3. C, control serum
compared. The ratios were significantly higher in ovarian
(P < 0.001) and endometrial (P < 0.01) cancer tissues than in
cervical cancer tissue. Moreover, the ratio was significantly higher
in ovarian cancer tissue than in endometrial cancer tissue
(P <0.05). The mean ratio in ovarian cancertissue was higherthan
in normal ovary and that in endometrial cancer tissue was higher
than in normal endometrium, although there was no significant
difference between normal and malignant tissue.
As for the relationship between hyaluronidase activity and
clinicopathological factors, high hyaluronidase activity was
observed in the patients with clear cell adenocarcinoma of the
ovary and hepatoid tumour of the endometrium, which are known
to have a poor prognosis.
Hyaluronidase activity was not observed at all at pH 5.0.
DISCUSSION
The enzymes that have been most frequently associated with
matrix degradation at the tumour invasion zone are the proteinases
and glycosidases. Many investigators have reported a positive
correlation between the expression ofproteinase and tumour inva-
siveness (Yamagata et al, 1988; Tamakoshi et al, 1994; Duffy et al,
1995). Although glycosidases have been investigated in less detail
than proteinases with regard to invasiveness and metastatic poten-
tial of cancer cells, specific glycosidases have been associated
with degradation of the basement membrane. Nakajima et al
(1984) showed that B16 melanoma cells synthesize a heparan
sulphate-specific endoglucuronidase (heparanase). Highly meta-
static B16 sublines degrade purified heparan sulphate preferen-
tially and at higher rates than B16 sublines of lower metastatic
potential. Similar results have been reported for methylcholan-
threne-induced T-lymphoma cells of varying metastatic potential
(Vlodavsky et al, 1983). However, few studies on hyaluronidase
have been reported as available techniques do not provide
adequate sensitivity for detecting small amounts of enzyme. To
our knowledge, no studies have analysed hyaluronidase activity
in clinical specimens. In this study, hyaluronidase activity in
gynaecological normal and cancer tissues was evaluated.
Expression ofmatrix-degrading enzyme activity is locally regu-
lated by concentration of tissue- and/or plasma-derived enzyme
inhibitors (Woolly, 1984; Khokhar and Denhardt, 1989; Baker et
al, 1990), pH level (Woolly, 1984), concentrations ofion and other
cofactors (Woolly, 1984) and activation of latent or proenzymes
(Woolly, 1984; Nagase et al, 1990). Among these regulators, pH is
the most controversial. Most glycosidases are lysosomal in origin
and are active at low pH. In our study, hyaluronidase in culture
medium obtained from normal and cancer tissues showed its peak
activity at pH 3.5. It is generally assumed that the pH of normal
tissue is neutral, making it impossible for enzymes with low pH
optima to act. However, many tumours are known to release
increased amounts of lactic acid (Warburg, 1956), thereby
producing an acidic microenvironment in which lysosomal
enzymes may be fully active. Hyaluronidase may be active only in
and around cancer tissue. Hyaluronidase activity was observed
strongly in normal and malignant tissues ofboth the ovary and the
endometrium but was hardly observed in those of the cervix.
These results suggest that the cancer cells make use ofthe original
characteristic ofthe organ to invade and metastasize.
Clinically, metastatic forms are different according to cancer
type. From the viewpoint of gynaecological cancer, the main
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metastatic routes ofovarian cancer are made through the abdominal
cavity in a disseminated manner and through the retroperitoneum
along the lymph node system. The degree ofdisseminated lesions is
considered to be important in determining prognosis (Rosman et al,
1994). In endometrial cancer, the dissemination of cancer cells is
seen in some cases but is rarely observed in cervical cancer. Human
mesothelial cells, which constitute the lining of the peritoneum,
produce large amounts of hyaluronic acid. In our study,
hyaluronidase activity was significantly higher in ovarian and
endometrial cancer tissues than in cervical cancer tissue. Moreover,
the activity was significantly higher in ovarian cancer tissue than in
endometrial cancer tissue. These results reflect the differences in
metastatic forms and are suggestive of a strong relationship
between hyaluronidase activity and invasion and metastasis of
ovarian and endometrial cancers compared with cervical cancer.
Various studies on the production of matrix-degrading enzyme-
specific inhibitors and their inhibitory substances are currently in
progress with a view towards development of anti-metastatic and
anti-invasive agents for clinical use (Nakajima et al, 1989; Saiki et
al, 1990; Jenks, 1992; Kobayashi et al, 1995). It is therefore impor-
tant to clarify the differences in glycosidase activities in different
metastatic types of cancer tissues. In the present study, gynaeco-
logical cancer tissues that have different metastatic forms show
different hyaluronidase activities. We hope that our findings will
contribute to the treatment of gynaecological cancer and we are
currently involved in further studies on invasion and metastasis
mechanisms in such diseases.
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